Clene Announced Long-term Follow-up Data For Patients Treated With CNM-au8 30Mg For Up To 133 Weeks In The HEALEY ALS Platform Trial, Showing Improved Survival With A 49% Decreased Risk Of Death
Portfolio Pulse from Benzinga Newsdesk
Clene has announced long-term follow-up data for patients treated with CNM-Au8 30mg for up to 133 weeks in the HEALEY ALS Platform Trial. The data shows improved survival with a 49% decreased risk of death.
September 25, 2023 | 11:06 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Clene's announcement of positive long-term data for its CNM-Au8 30mg treatment could potentially boost investor confidence and positively impact its stock price.
The announcement of positive long-term data for a company's product typically boosts investor confidence, as it indicates the product's effectiveness and potential for market success. This could lead to increased demand for the company's stock, thereby driving up its price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100